{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:03:29Z","timestamp":1790521409791,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Farma S.p.A"},{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>First-generation somatostatin analogs, octreotide (OCT) and lanreotide, are the cornerstone for the medical treatment of growth hormone (GH)-secreting pituitary tumors. A new multireceptor analog, such as pasireotide (PAS), showed better activity than OCT in long-term treatment of patients with acromegaly, but modulation of intracellular key processes is still unclear in vitro. In this study, we evaluated the antitumor activity of OCT and PAS in two GH-secreting pituitary tumor cell lines, GH3 and GH4C1, after a long-term incubation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The effects of PAS and OCT on the cell viability, cell cycle, apoptosis, GH secretion, and tumor-induced angiogenesis have been evaluated through a colorimetric method (MTS Assay), DNA flow cytometry with propidium iodide, and Annexin V-FITC\/propidium iodide staining, ELISA assay and zebrafish platform, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>PAS showed a more potent antitumor activity compared to OCT in GH3 cell line exerted through inhibition of cell viability, perturbation of cell cycle progression, and induction of apoptosis after 6\u00a0days of incubation. A concomitant decrease in GH secretion has been observed after 2\u00a0days of incubation only with PAS. No effect on tumor-induced angiogenesis has been reported after treatment with OCT or PAS in zebrafish\/tumor xenograft model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Long-term incubation with PAS showed a more potent antitumor activity than that reported after OCT in GH3 cells, mainly modulated by a cell cycle perturbation and a relevant induction in apoptosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-021-01609-1","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T21:02:32Z","timestamp":1623704552000},"page":"29-41","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-term effects of somatostatin analogues in rat GH-secreting pituitary tumor cell lines"],"prefix":"10.1007","volume":"45","author":[{"given":"A.","family":"Dicitore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Saronni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gaudenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Carra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Cantone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. O.","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Persani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2478-683X","authenticated-orcid":false,"given":"G.","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"issue":"5","key":"1609_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","volume":"21","author":"A Colao","year":"2019","unstructured":"Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, Pivonello R (2019) Acromegaly. Nat Rev Dis Primers 21(5):20. https:\/\/doi.org\/10.1038\/s41572-019-0071-6","journal-title":"Nat Rev Dis Primers"},{"key":"1609_CR2","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Hassan Murad M, Utz A, Wass JAH (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:3933\u20133951. https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"},{"key":"1609_CR3","doi-asserted-by":"publisher","first-page":"R223","DOI":"10.1530\/JME-14-0011","volume":"52","author":"D Cuevas-Ramos","year":"2014","unstructured":"Cuevas-Ramos D, Fleseriu M (2014) Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. J Mol Endocrinol 52:R223\u2013R240. https:\/\/doi.org\/10.1530\/JME-14-0011","journal-title":"J Mol Endocrinol"},{"key":"1609_CR4","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, Strasburger CJ, Luger A, Clemmons DR, Giustina A (2018) Consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14:552\u2013556. https:\/\/doi.org\/10.1038\/s41574-018-0058-5","journal-title":"Nat Rev Endocrinol"},{"key":"1609_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.23736\/S0391-1977.18.02937-1","volume":"44","author":"M Puig-Domingo","year":"2019","unstructured":"Puig-Domingo M, Marazuela M (2019) Precision medicine in the treatment of acromegaly. Minerva Endocrinol 44:169\u2013175. https:\/\/doi.org\/10.23736\/S0391-1977.18.02937-1","journal-title":"Minerva Endocrinol"},{"key":"1609_CR6","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1210\/jc.2005-2347","volume":"91","author":"R Cozzi","year":"2006","unstructured":"Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G (2006) Primary treatment of acromegaly with octreotide LAR: long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 91:1397\u20131403. https:\/\/doi.org\/10.1210\/jc.2005-2347","journal-title":"J Clin Endocrinol Metab"},{"key":"1609_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.23736\/S0391-1977.19.02970-5","volume":"44","author":"AC Fuentes-Fayos","year":"2019","unstructured":"Fuentes-Fayos AC, Garc\u00eda-Mart\u00ednez A, Herrera-Mart\u00ednez AD, Jim\u00e9nez-Vacas JM, V\u00e1zquez-Borrego MC, Casta\u00f1o JP, Pic\u00f3 A, Gahete MD, Luque RM (2019) Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors. Minerva Endocrinol 44:109\u2013128. https:\/\/doi.org\/10.23736\/S0391-1977.19.02970-5","journal-title":"Minerva Endocrinol"},{"key":"1609_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.23736\/S0391-1977.18.02933-4","volume":"44","author":"J Trouillas","year":"2019","unstructured":"Trouillas J, Vasiljevic A, Lapoirie M, Chinezu L, Jouanneau E, Raverot G (2019) Pathological markers of somatotroph pituitary neuroendocrine tumors predicting the response to medical treatment. Minerva Endocrinol 44:129\u2013136. https:\/\/doi.org\/10.23736\/S0391-1977.18.02933-4","journal-title":"Minerva Endocrinol"},{"key":"1609_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11102-017-0791-0","volume":"20","author":"MR Gadelha","year":"2017","unstructured":"Gadelha MR, Wildemberg LE, Bronstein MD, Gatto F, Ferone D (2017) Somatostatin receptor ligands in the treatment of acromegaly. Pituitary 20:100\u2013108. https:\/\/doi.org\/10.1007\/s11102-017-0791-0","journal-title":"Pituitary"},{"key":"1609_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1210\/er.2010-0002","volume":"32","author":"A Colao","year":"2011","unstructured":"Colao A, Auriemma RS, Lombardi G, Pivonello R (2011) Resistance to somatostatin analogs in acromegaly. Endocr Rev 32:247\u2013271. https:\/\/doi.org\/10.1210\/er.2010-0002","journal-title":"Endocr Rev"},{"key":"1609_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40265-018-1033-0","volume":"79","author":"AD Herrera-Mart\u00ednez","year":"2019","unstructured":"Herrera-Mart\u00ednez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, G\u00e1lvez Moreno MA, Luque RM, Casta\u00f1o JP, de Herder WW, Feelders RA (2019) Targeted systemic treatment of neuroendocrine tumors: current options and future perspectives. Drugs 79:21\u201342. https:\/\/doi.org\/10.1007\/s40265-018-1033-0","journal-title":"Drugs"},{"key":"1609_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1210\/er.2000-0001","volume":"24","author":"LJ Hofland","year":"2003","unstructured":"Hofland LJ, Lamberts SWJ (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24:28\u201347. https:\/\/doi.org\/10.1210\/er.2000-0001","journal-title":"Endocr Rev"},{"key":"1609_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.23736\/S0391-1977.19.02972-9","volume":"44","author":"A Pic\u00f2","year":"2019","unstructured":"Pic\u00f2 A (2019) Acromegaly in the era of precision medicine. Minerva Endocrinol 44:105\u2013108. https:\/\/doi.org\/10.23736\/S0391-1977.19.02972-9","journal-title":"Minerva Endocrinol"},{"key":"1609_CR14","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s12020-018-1690-5","volume":"62","author":"I Shimon","year":"2018","unstructured":"Shimon I, Adnan A, Gorshtein A, Baraf L, Khazen NS, Gershinsky M, Pauker Y, Abid A, Niven MJ, Shechner C, Greenman Y (2018) Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Endocrine 62:448\u2013455. https:\/\/doi.org\/10.1007\/s12020-018-1690-5","journal-title":"Endocrine"},{"key":"1609_CR15","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1210\/jc.2008-1919","volume":"94","author":"S Lesche","year":"2009","unstructured":"Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S (2009) Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab 94:654\u2013661. https:\/\/doi.org\/10.1210\/jc.2008-1919","journal-title":"J Clin Endocrinol Metab"},{"key":"1609_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s11102-015-0677-y","volume":"19","author":"A Colao","year":"2016","unstructured":"Colao A, Pivonello R (2016) The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary 19:210\u2013221. https:\/\/doi.org\/10.1007\/s11102-015-0677-y","journal-title":"Pituitary"},{"key":"1609_CR17","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A (2014) Pasireotide C2402 Study Group. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2:875\u2013884. https:\/\/doi.org\/10.1016\/S2213-8587(14)70169-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1609_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s11102-013-0478-0","volume":"17","author":"S Petersenn","year":"2014","unstructured":"Petersenn S, Farrall AJ, De Block C, Melmed S, Schopohl J, Caron P, Cuneo R, Kleinberg D, Colao A, Ruffin M, Hermosillo Res\u00e9ndiz K, Hughes G, Hu K, Barkan A (2014) Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, phase II extension study. Pituitary 17:132\u2013140. https:\/\/doi.org\/10.1007\/s11102-013-0478-0","journal-title":"Pituitary"},{"key":"1609_CR19","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Res\u00e9ndiz K, Ruffin M, Chen Y, Sheppard M (2014) Pasireotide C2305 Study Group: pasireotide versus octreotide in acromegaly: a head- to-head superiority study. J Clin Endocrinol Metab 99:791\u2013799. https:\/\/doi.org\/10.1210\/jc.2013-2480","journal-title":"J Clin Endocrinol Metab"},{"key":"1609_CR20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ejogrb.2018.10.004","volume":"230","author":"A Dicitore","year":"2018","unstructured":"Dicitore A, Castiglioni S, Saronni D, Gentilini D, Borghi MO, Stabile S, Vignali M, Di Blasio AM, Persani L, Vitale G (2018) Effects of human recombinant type I IFNs (IFN-\u03b12b and IFN-\u03b21a) on growth and migration of primary endometrial stromal cells from women with deeply infiltrating endometriosis: a preliminary study. Eur J Obstet Gynecol Reprod Biol 230:192\u2013198. https:\/\/doi.org\/10.1016\/j.ejogrb.2018.10.004","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1609_CR21","doi-asserted-by":"publisher","first-page":"393","DOI":"10.23736\/S0391-1977.20.03371-4","volume":"45","author":"S Carra","year":"2020","unstructured":"Carra S, Gaudenzi G (2020) New perspectives in neuroendocrine neoplasms research from tumor xenografts in zebrafish embryos. Minerva Endocrinol 45:393\u2013394. https:\/\/doi.org\/10.23736\/S0391-1977.20.03371-4","journal-title":"Minerva Endocrinol"},{"key":"1609_CR22","doi-asserted-by":"publisher","first-page":"R67","DOI":"10.1530\/ERC-13-0388","volume":"21","author":"G Vitale","year":"2014","unstructured":"Vitale G, Gaudenzi G, Dicitore A, Cotelli F, Ferone D, Persani L (2014) Zebrafish as an innovative model for neuroendocrine tumors. Endocr Relat Cancer 21:R67-83. https:\/\/doi.org\/10.1530\/ERC-13-0388","journal-title":"Endocr Relat Cancer"},{"key":"1609_CR23","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s12020-016-1048-9","volume":"57","author":"G Gaudenzi","year":"2017","unstructured":"Gaudenzi G, Albertelli M, Dicitore A, W\u00fcrth R, Gatto F, Barbieri F, Cotelli F, Florio T, Ferone D, Persani L, Vitale G (2017) Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors. Endocrine 57:214\u2013219. https:\/\/doi.org\/10.1007\/s12020-016-1048-9","journal-title":"Endocrine"},{"key":"1609_CR24","doi-asserted-by":"publisher","first-page":"e51245","DOI":"10.1371\/journal.pone.0051245","volume":"7","author":"S Carra","year":"2012","unstructured":"Carra S, Foglia E, Cermenati S, Bresciani E, Giampietro C, Lora Lamia C, Dejana E, Beltrame M, Cotelli F (2012) Ve-ptp modulates vascular integrity by promoting adherens junction maturation. PLoS ONE 7:e51245. https:\/\/doi.org\/10.1371\/journal.pone.0051245","journal-title":"PLoS ONE"},{"key":"1609_CR25","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/nrd1255","volume":"2","author":"G Weckbecker","year":"2003","unstructured":"Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C (2003) Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discovery 2:999\u20131017. https:\/\/doi.org\/10.1038\/nrd1255","journal-title":"Nat Rev Drug Discovery"},{"key":"1609_CR26","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/annonc\/mdl105","volume":"17","author":"C Susini","year":"2006","unstructured":"Susini C, Buscail L (2006) Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 17:1733\u20131742. https:\/\/doi.org\/10.1093\/annonc\/mdl105","journal-title":"Ann Oncol"},{"key":"1609_CR27","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/bf03349589","volume":"13","author":"G Pelicci","year":"1990","unstructured":"Pelicci G, Pagliacci MC, Lanfrancone L, Pelicci PG, Grignani F, Nicoletti I (1990) Inhibitory effect of the somatostatin analog octreotide on rat pituitary tumor cell (GH3) proliferation in vitro. J Endocrinol Invest 13:657\u2013662. https:\/\/doi.org\/10.1007\/bf03349589","journal-title":"J Endocrinol Invest"},{"key":"1609_CR28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1530\/eje.1.02213","volume":"155","author":"E Hubina","year":"2006","unstructured":"Hubina E, Nanzer AM, Hanson MR, Ciccarelli E, Losa M, Gaia D, Papotti M, Terreni MR, Khalaf S, Jordan S, Czirj\u00e1k S, Hanz\u00e9ly Z, Nagy GM, G\u00f3th MI, Grossman AB, Korbonits M (2006) Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol 155:371\u2013379. https:\/\/doi.org\/10.1530\/eje.1.02213","journal-title":"Eur J Endocrinol"},{"key":"1609_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1530\/JOE-16-0332","volume":"231","author":"A Ib\u00e1\u00f1ez-Costa","year":"2016","unstructured":"Ib\u00e1\u00f1ez-Costa A, Rivero-Cort\u00e9s E, V\u00e1zquez-Borrego MC, Gahete MD, Jim\u00e9nez-Reina L, Venegas-Moreno E, de la Riva A, Arr\u00e1ez MA, Gonz\u00e1lez-Molero I, Schmid HA, Maraver-Selfa S, Gavil\u00e1n-Villarejo I, Garc\u00eda-Arn\u00e9s JA, Jap\u00f3n MA, Soto-Moreno A, G\u00e1lvez MA, Luque RM, Casta\u00f1o JP (2016) Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro. J Endocrinol 231:135\u2013145. https:\/\/doi.org\/10.1530\/JOE-16-0332","journal-title":"J Endocrinol"},{"key":"1609_CR30","doi-asserted-by":"publisher","first-page":"13869","DOI":"10.1074\/jbc.272.21.13869","volume":"272","author":"RW Hipkin","year":"1997","unstructured":"Hipkin RW, Friedman J, Clark RB, Eppler CM, Schonbrunn A (1997) Agonist-induced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor. J Biol Chem 272:13869\u201313876. https:\/\/doi.org\/10.1074\/jbc.272.21.13869","journal-title":"J Biol Chem"},{"key":"1609_CR31","first-page":"402","volume":"45","author":"PD Garcia","year":"1994","unstructured":"Garcia PD, Myers RM (1994) Pituitary cell line GH3 expresses two somatostatin receptor subtypes that inhibit adenylyl cyclase: functional expression of rat somatostatin receptor subtypes 1 and 2 in human embryonic kidney 293 cells. Mol Pharmacol 45:402\u2013409","journal-title":"Mol Pharmacol"},{"key":"1609_CR32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0014-5793(94)00444-7","volume":"345","author":"F Hauser","year":"1994","unstructured":"Hauser F, Meyerhof W, Wulfsen I, Sch\u00f6nrock C, Richter D (1994) Sequence analysis of the promoter region of the rat somatostatin receptor subtype 1 gene. FEBS Lett 345:225\u2013228. https:\/\/doi.org\/10.1016\/0014-5793(94)00444-7","journal-title":"FEBS Lett"},{"key":"1609_CR33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1210\/mend.14.2.0419","volume":"14","author":"H Baumeister","year":"2000","unstructured":"Baumeister H, Wegner M, Richter D, Meyerhof W (2000) Dual regulation of somatostatin receptor subtype 1 gene expression by pit-1 in anterior pituitary GH3 cells. Mol Endocrinol 14:255\u2013271. https:\/\/doi.org\/10.1210\/mend.14.2.0419","journal-title":"Mol Endocrinol"},{"key":"1609_CR34","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1210\/me.2007-0068","volume":"22","author":"E Peverelli","year":"2008","unstructured":"Peverelli E, Mantovani G, Calebiro D, Doni A, Bondioni S, Lania A, Beck-Peccoz P, Spada A (2008) The third intracellular loop of the human somatostatin receptor 5 is crucial for arrestin binding and receptor internalization after somatostatin stimulation. Mol Endocrinol 22:676\u2013688. https:\/\/doi.org\/10.1210\/me.2007-0068","journal-title":"Mol Endocrinol"},{"key":"1609_CR35","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.1210\/endo.136.11.7588243","volume":"136","author":"Y Xu","year":"1995","unstructured":"Xu Y, Berelowitz M, Bruno JF (1995) Dexamethasone regulates somatostatin receptor subtype messenger ribonucleic acid expression in rat pituitary GH4C1 cells. Endocrinology 136:5070\u20135075. https:\/\/doi.org\/10.1210\/endo.136.11.7588243","journal-title":"Endocrinology"},{"key":"1609_CR36","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1210\/me.2009-0315","volume":"24","author":"F P\u00f6ll","year":"2010","unstructured":"P\u00f6ll F, Lehmann D, Illing S, Ginj M, Jacobs S, Lupp A, Stumm R, Schulz S (2010) Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Mol Endocrinol 24:436\u2013446. https:\/\/doi.org\/10.1210\/me.2009-0315","journal-title":"Mol Endocrinol"},{"key":"1609_CR37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.mce.2014.02.009","volume":"387","author":"A Lehmann","year":"2014","unstructured":"Lehmann A, Kliewer A, Schutz D, Nagel F, Stumm R, Schulz S (2014) Carboxyl-terminal multi-site phosphorylation regulates internalization and desensitization of the human sst2 somatostatin receptor. Mol Cell Endocrinol 387:44\u201351. https:\/\/doi.org\/10.1016\/j.mce.2014.02.009","journal-title":"Mol Cell Endocrinol"},{"key":"1609_CR38","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1210\/me.2010-0398","volume":"25","author":"YJ Kao","year":"2011","unstructured":"Kao YJ, Ghosh M, Schonbrunn A (2011) Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists. Mol Endocrinol 25:1040\u20131054. https:\/\/doi.org\/10.1210\/me.2010-0398","journal-title":"Mol Endocrinol"},{"key":"1609_CR39","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1530\/ERC-14-0086","volume":"21","author":"A Mohamed","year":"2014","unstructured":"Mohamed A, Blanchard MP, Albertelli M, Barbieri F, Brue T, Niccoli P, Delpero JR, Monges G, Garcia S, Ferone D, Florio T, Enjalbert A, Moutardier V, Schonbrunn A, Gerard C, Barlier A, Saveanu A (2014) Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures. Endoc Relat Cancer 21:691\u2013704. https:\/\/doi.org\/10.1530\/ERC-14-0086","journal-title":"Endoc Relat Cancer"},{"key":"1609_CR40","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3390\/cancers13081816","volume":"13","author":"J Amar\u00f9","year":"2021","unstructured":"Amar\u00f9 J, Barbieri F, Arvigo M, Solari A, Bajetto A, Nista F, Campana C, Gaggero G, Prior A, Criminelli Rossi D, Zona G, Ferone D, Florio T, Gatto F (2021) Octreotide and Pasireotide combination treatment in somatotroph tumor cells: predominant role of SST2 in mediating ligand effects. Cancers 13:1816. https:\/\/doi.org\/10.3390\/cancers13081816","journal-title":"Cancers"},{"key":"1609_CR41","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.tem.2013.11.003","volume":"25","author":"M Chalabi","year":"2014","unstructured":"Chalabi M, Duluc C, Caron P, Vezzosi D, Guillermet-Guibert J, Pyronnet S, Bousquet C (2014) Somatostatin analogs: does pharmacology impact antitumor efficacy? Trends Endocrinol Metab 25:115\u2013127. https:\/\/doi.org\/10.1016\/j.tem.2013.11.003","journal-title":"Trends Endocrinol Metab"},{"key":"1609_CR42","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1210\/endo.136.10.7664634","volume":"136","author":"NW Cheung","year":"1995","unstructured":"Cheung NW, Boyages SC (1995) Somatostatin-14 and its analog octreotide exert a cytostatic effect on GH3 rat pituitary tumor cell proliferation via a transient G0\/G1 cell cycle block. Endocrinology 136:4174\u20134181. https:\/\/doi.org\/10.1210\/endo.136.10.7664634","journal-title":"Endocrinology"},{"key":"1609_CR43","doi-asserted-by":"publisher","first-page":"G245","DOI":"10.1152\/ajpgi.1994.267.2.G245","volume":"267","author":"A Todisco","year":"1994","unstructured":"Todisco A, Campbell V, Dickinson CJ, DelValle J, Yamada T (1994) Molecular basis for somatostatin action: inhibition of c-fos expression and AP-1 binding. Am J Physiol 267:G245\u2013G253. https:\/\/doi.org\/10.1152\/ajpgi.1994.267.2.G245","journal-title":"Am J Physiol"},{"key":"1609_CR44","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1210\/jc.2006-2084","volume":"92","author":"E Resmini","year":"2007","unstructured":"Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, Jaquet P, Culler MD, Bianchi F, Rebora A, Minuto F, Ferone D (2007) Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 92:1592\u20131529. https:\/\/doi.org\/10.1210\/jc.2006-2084","journal-title":"J Clin Endocrinol Metab"},{"key":"1609_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11102-006-7822-6","volume":"9","author":"MC Zatelli","year":"2006","unstructured":"Zatelli MC, Piccin D, Ambrosio MR, Bondanelli M, degli Uberti EC (2006) Antiproliferative effects of somatostatin analogs in pituitary adenomas. Pituitary 9:27\u201334. https:\/\/doi.org\/10.1007\/s11102-006-7822-6","journal-title":"Pituitary"},{"key":"1609_CR46","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1159\/000054651","volume":"73","author":"G Tulipano","year":"2001","unstructured":"Tulipano G, Bonfanti C, Milani G, Billeci B, Bollati A, Cozzi R, Maira G, Murphy WA, Poiesi C, Turazzi S, Giustina A (2001) Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro. Neuroendocrinology 73:344\u2013351. https:\/\/doi.org\/10.1159\/000054651","journal-title":"Neuroendocrinology"},{"key":"1609_CR47","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.envres.2019.04.007","volume":"173","author":"V Zunino","year":"2019","unstructured":"Zunino V, Catalano MG, Zenga F, Penner F, Maletta F, Valerio F, Rinella L, Arvat E, Fortunati N (2019) Benzene affects the response to octreotide treatment of growth hormone secreting pituitary adenoma cells. Environ Res 173:489\u2013496. https:\/\/doi.org\/10.1016\/j.envres.2019.04.007","journal-title":"Environ Res"},{"key":"1609_CR48","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1179\/174313208X289499","volume":"30","author":"M Kurosaki","year":"2008","unstructured":"Kurosaki M, Saegert W, Abe T, L\u00fcdecke DK (2008) Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment. Neurol Res 30:518\u2013522. https:\/\/doi.org\/10.1179\/174313208X289499","journal-title":"Neurol Res"},{"key":"1609_CR49","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1210\/jc.2007-1358","volume":"93","author":"D Ferone","year":"2008","unstructured":"Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, Minuto F, Colao A, Lamberts SWJ, Hofland LJ (2008) Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab 93:1412\u20131417. https:\/\/doi.org\/10.1210\/jc.2007-1358","journal-title":"J Clin Endocrinol Metab"},{"key":"1609_CR50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11102-018-0926-y","volume":"22","author":"F Gatto","year":"2019","unstructured":"Gatto F, Arvigo M, Amar\u00f9 J, Campana C, Cocchiara F, Graziani G, Bruzzone E, Giusti M, Boschetti M, Ferone D (2019) Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells. Pituitary 22:89\u201399. https:\/\/doi.org\/10.1007\/s11102-018-0926-y","journal-title":"Pituitary"},{"key":"1609_CR51","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2265.1992.tb02317.x","volume":"37","author":"LJ Hofland","year":"1992","unstructured":"Hofland LJ, Velkeniers B, vd Lely AJ, van Koetsveld PM, Kazemzadeh M, Waaijers M, Hooghe-Peters EL, Lamberts SW (1992) Long-term in-vitro treatment of human growth hormone (GH)-secreting pituitary adenoma cells with octreotide causes accumulation of intracellular GH and GH mRNA levels. Clin Endocrinol 37:240\u2013248. https:\/\/doi.org\/10.1111\/j.1365-2265.1992.tb02317.x","journal-title":"Clin Endocrinol"},{"key":"1609_CR52","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/j.1365-2362.2007.01848.x","volume":"37","author":"G Bocci","year":"2007","unstructured":"Bocci G, Culler MD, Fioravanti A, Orlandi P, Fasciani A, Colucci R, Taylor JE, Sadat D, Danesi R, Del Tacca M (2007) In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists. Eur J Clin Invest 37:700\u2013708. https:\/\/doi.org\/10.1111\/j.1365-2362.2007.01848.x","journal-title":"Eur J Clin Invest"},{"key":"1609_CR53","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/sj.bjc.6602503","volume":"92","author":"RL Adams","year":"2005","unstructured":"Adams RL, Adams IP, Lindow SW, Zhong W, Atki SL (2005) Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer 92:1493\u20131498. https:\/\/doi.org\/10.1038\/sj.bjc.6602503","journal-title":"Br J Cancer"},{"key":"1609_CR54","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1210\/me.2004-0280","volume":"19","author":"S Arena","year":"2005","unstructured":"Arena S, Pattarozzi A, Corsaro A, Schettini G, Florio T (2005) Somatostatin receptor subtype-dependent regulation of nitric oxide release: involvement of different intracellular pathways. Mol Endocrinol 19:255\u2013267. https:\/\/doi.org\/10.1210\/me.2004-0280","journal-title":"Mol Endocrinol"},{"key":"1609_CR55","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s004280000373","volume":"438","author":"S Vidal","year":"2001","unstructured":"Vidal S, Kovacs K, Horvath E, Scheithauer BW, Kuroki T, Lloyd RV (2001) Microvessel density in pituitary adenomas and carcinomas. Virchows Arch 438:595\u2013602. https:\/\/doi.org\/10.1007\/s004280000373","journal-title":"Virchows Arch"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01609-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-021-01609-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01609-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T19:15:10Z","timestamp":1641582910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-021-01609-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1609"],"URL":"https:\/\/doi.org\/10.1007\/s40618-021-01609-1","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,14]]},"assertion":[{"value":"13 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Ethics Committee (Approval number: 2017_09_27_04).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study Informed consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}